Patent application number | Description | Published |
20090048227 | Substituted-1-Phthalazinamines As Vr- 1 Antagonists - Substituted piperidine compounds represented by Formula I, or pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprise an effective amount of the instant compounds, either alone, or in combination with one or more other therapeutically active compounds, and a pharmaceutically acceptable carrier. Methods of treating conditions associated with, or caused by, sodium channel activity, including, for example, acute pain, chronic pain, visceral pain, inflammatory pain, neuropathic pain, urinary incontinence, itchiness, allergic dermatitis, epilepsy, irritable bowel syndrome, depression, anxiety, multiple sclerosis, and bipolar disorder, comprise administering an effective amount of the present compounds, either alone, or in combination with one or more other therapeutically active compounds. | 02-19-2009 |
20100210620 | Substituted Aryl Sulfone Derivatives as Calcium Channel Blockers - A series of substituted aryl sulfone derivatives represented by Formula I, or pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprise an effective amount of the instant compounds, either alone, or in combination with one or more other therapeutically active compounds, and a pharmaceutically acceptable carrier. Methods of treating conditions associated with, or caused by, calcium channel activity, including, for example, acute pain, chronic pain, visceral pain, inflammatory pain, neuropathic pain, urinary incontinence, itchiness, allergic dermatitis, epilepsy, diabetic neuropathy, irritable bowel syndrome, depression, anxiety, multiple sclerosis, sleep disorder, bipolar disorder and stroke, comprise administering an effective amount of the present compounds, either alone, or in combination with one or more other therapeutically active compounds. | 08-19-2010 |
20120041012 | SUBSTITUTED SPIROCYCLIC AMINES USEFUL AS ANTIDIABETIC COMPOUNDS - Substituted spirocyclic amines of structural formula I are selective antagonists of the somatostatin sub-type receptor 5 (SSTR5) and are useful for the treatment, control or prevention of disorders responsive to antagonism of SSTR5, such as Type 2 diabetes, insulin resistance, lipid disorders, obesity, atherosclerosis, metabolic syndrome, depression, and anxiety. | 02-16-2012 |
20130040932 | SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS - A series of substituted aryl sulfone derivatives represented by Formula I, or pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprise an effective amount of the instant compounds, either alone, or in combination with one or more other therapeutically active compounds, and a pharmaceutically acceptable carrier. Methods of treating conditions associated with, or caused by, calcium channel activity, including, for example, acute pain, chronic pain, visceral pain, inflammatory pain, neuropathic pain, urinary incontinence, itchiness, allergic dermatitis, epilepsy, diabetic neuropathy, irritable bowel syndrome, depression, anxiety, multiple sclerosis, sleep disorder, bipolar disorder and stroke, comprise administering an effective amount of the present compounds, either alone, or in combination with one or more other therapeutically active compounds. | 02-14-2013 |
20130040978 | SPIRO ISOXAZOLINE COMPOUNDS AS SSTR5 ANTAGONISTS - Substituted spirocyclic amines of structural formula (I) are selective antagonists of the somatostatin subtype receptor 5 (SSTR5) and are useful for the treatment, control or prevention of disorders responsive to antagonism of SSTR5, such as Type 2 diabetes, insulin resistance, lipid disorders, obesity, atherosclerosis, Metabolic Syndrome, depression, and anxiety. | 02-14-2013 |
20130109649 | FUSED BICYCLIC OXAZOLIDINONE CETP INHIBITOR | 05-02-2013 |
20130131042 | SPIROXAZOLIDINONE COMPOUNDS - Substituted spirocyclic amines of structural formula (I) are selective antagonists of the somatostatin subtype receptor 5 (SSTR5) and are useful for the treatment, control or prevention of disorders responsive to antagonism of SSTR5, such as Type 2 diabetes, insulin resistance, lipid disorders, obesity, atherosclerosis, Metabolic Syndrome, depression, and anxiety. | 05-23-2013 |
20140378493 | Fused Bicyclic Oxazolidinone CETP Inhibitor - Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. | 12-25-2014 |
20150111866 | CYCLIC AMINE SUBSTITUTED HETEROCYCLIC CETP INHIBITORS - Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and may be useful for raising HDL-cholesterol and reducing LDL-cholesterol in human patients and for treating or preventing atherosclerosis. | 04-23-2015 |
Patent application number | Description | Published |
20080206343 | Hepatocytes and Chondrocytes from Adherent Placental StemCells; And CD34+ ,CD45- Placental Stem Cell-Enriched Cell Populations - Provided herein are methods and compositions for the production of hepatocytes from placenta stem cells. Further provided herein is the use of such hepatocytes in the treatment of, and intervention in, for example, trauma, inflammation, and degenerative disorders of the liver. Also provided herein are compositions and methods relating to combinations of nanofibrous scaffolds and adherent placental stem cells and methods of using the same in cartilage repair. Finally, provided herein are compositions and methods relating to nonadherent, CD34 | 08-28-2008 |
20080213228 | Methods and Compositions for Treatment of Bone Defects with Placental Cell Populations - Provided herein are methods of using adherent placental stem cells and placental stem cell populations, and methods of culturing, proliferating and expanding the same. Also provided herein are methods of differentiating the placental stem cells. Further provided herein are methods of using the placental stem cells to formulate implantable or injectable compositions suitable for administration to a subject. Still further provided herein are provides methods for treating bone defects with stem cells and compositions comprising stem cells. | 09-04-2008 |
20080226595 | TREATMENT OF INFLAMMATORY DISEASES USING PLACENTAL STEM CELLS - Provided herein are methods of treatment of individuals having an immune-related disease, disorder or condition, for example, inflammatory bowel disease, graft-versus-host disease, multiple sclerosis, rheumatoid arthritis, psoriasis, lupus erythematosus, diabetes, mycosis fungoides (Alibert-Bazin syndrome), or scleroderma using placental stem cells or umbilical cord stem cells. | 09-18-2008 |
20100297689 | PLACENTAL STEM CELL POPULATIONS - The present invention provides placental stem cells and placental stem cell populations, and methods of culturing, proliferating and expanding the same. The invention also provides methods of differentiating the placental stem cells. The invention further provides methods of using the placental stem cells in assays and for transplanting. | 11-25-2010 |
20110250185 | TUMOR SUPPRESSION USING PLACENTAL STEM CELLS - The present invention provides methods of suppression of tumor cell proliferation and tumor growth using placental stem cells and placental stem cell populations. The invention also provides methods of producing and selecting placental cells and cell populations on the basis of tumor suppression, and compositions comprising such cells and cell populations. | 10-13-2011 |
20110280843 | TREATMENT OF DISEASES AND DISORDERS USING PLACENTAL STEM CELLS - Provided herein are methods of treatment of individuals having an immune-related disease, disorder or condition, for example, inflammatory bowel disease, graft-versus-host disease, multiple sclerosis, rheumatoid arthritis, psoriasis, lupus erythematosus, diabetes, mycosis fungoides (Alibert-Bazin syndrome), or scleroderma using placental stem cells or umbilical cord stem cells. | 11-17-2011 |
20110280845 | TREATMENT OF RHEUMATOID ARTHRITIS USING PLACENTAL STEM CELLS - Provided herein are methods of treatment of individuals having an immune-related disease, disorder or condition, for example, inflammatory bowel disease, graft-versus-host disease, multiple sclerosis, rheumatoid arthritis, psoriasis, lupus erythematosus, diabetes, mycosis fungoides (Alibert-Bazin syndrome), or scleroderma using placental stem cells or umbilical cord stem cells. | 11-17-2011 |
20110306755 | HUMAN PLACENTAL COLLAGEN COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME - The present invention provides compositions comprising human placental telopeptide collagen, methods of preparing the compositions, methods of their use and kits comprising the compositions. The compositions, kits and methods are useful, for example, for augmenting or replacing tissue of a mammal. | 12-15-2011 |
20120122215 | PLACENTAL STEM CELL POPULATIONS - The present invention provides placental stem cells and placental stem cell populations, and methods of culturing, proliferating and expanding the same. The invention also provides methods of differentiating the placental stem cells. The invention further provides methods of using the placental stem cells in assays and for transplanting. | 05-17-2012 |
20120225484 | HUMAN PLACENTAL COLLAGEN COMPOSITIONS, AND METHODS OF MAKING AND USING THE SAME - The present invention provides compositions comprising human placental telopeptide collagen, methods of preparing the compositions, methods of their use and kits comprising the compositions. The compositions, kits and methods are useful, for example, for augmenting or replacing tissue of a mammal. | 09-06-2012 |
20130022581 | PLACENTAL STEM CELL POPULATIONS - The present invention provides placental stem cells and placental stem cell populations, and methods of culturing, proliferating and expanding the same. The invention also provides methods of differentiating the placental stem cells. The invention further provides methods of using the placental stem cells in assays and for transplanting. | 01-24-2013 |
20130028871 | PLACENTAL STEM CELL POPULATIONS - The present invention provides placental stem cells and placental stem cell populations, and methods of culturing, proliferating and expanding the same. The invention also provides methods of differentiating the placental stem cells. The invention further provides methods of using the placental stem cells in assays and for transplanting. | 01-31-2013 |
20130071362 | HUMAN PLACENTAL COLLAGEN COMPOSITIONS, AND METHODS OF MAKING AND USING THE SAME - The present invention provides compositions comprising human placental telopeptide collagen, methods of preparing the compositions, methods of their use and kits comprising the compositions. The compositions, kits and methods are useful, for example, for augmenting or replacing tissue of a mammal. | 03-21-2013 |
20130172531 | HUMAN PLACENTAL COLLAGEN COMPOSITIONS, AND METHODS OF MAKING AND USING THE SAME - The present invention provides compositions comprising human placental telopeptide collagen, methods of preparing the compositions, methods of their use and kits comprising the compositions. The compositions, kits and methods are useful, for example, for augmenting or replacing tissue of a mammal. | 07-04-2013 |
20130231288 | HUMAN PLACENTAL COLLAGEN COMPOSITIONS, AND METHODS OF MAKING AND USING THE SAME - The present invention provides compositions comprising human placental telopeptide collagen, methods of preparing the compositions, methods of their use and kits comprising the compositions. The compositions, kits and methods are useful, for example, for augmenting or replacing tissue of a mammal. | 09-05-2013 |
20130344037 | TREATMENT OF INFLAMMATORY DISEASES USING PLACENTAL STEM CELLS - Provided herein are methods of treatment of individuals having an immune-related disease, disorder or condition, for example, inflammatory bowel disease, graft-versus-host disease, multiple sclerosis, rheumatoid arthritis, psoriasis, lupus erythematosus, diabetes, mycosis fungoides (Alibert-Bazin syndrome), or scleroderma using placental stem cells or umbilical cord stem cells. | 12-26-2013 |
20140011743 | HUMAN PLACENTAL COLLAGEN COMPOSITIONS, AND METHODS OF MAKING AND USING THE SAME - The present invention provides compositions comprising human placental telopeptide collagen, methods of preparing the compositions, methods of their use and kits comprising the compositions. The compositions, kits and methods are useful, for example, for augmenting or replacing tissue of a mammal. | 01-09-2014 |
20140017211 | METHODS AND COMPOSITIONS FOR TREATMENT OF BONE DEFECTS WITH PLACENTAL CELL POPULATIONS - Provided herein are methods of using adherent placental stem cells and placental stem cell populations, and methods of culturing, proliferating and expanding the same. Also provided herein are methods of differentiating the placental stem cells. Further provided herein are methods of using the placental stem cells to formulate implantable or injectable compositions suitable for administration to a subject. Still further provided herein are provides methods for treating bone defects with stem cells and compositions comprising stem cells. | 01-16-2014 |
20140377230 | Placental Stem Cell Populations - The present invention provides placental stem cells and placental stem cell populations, and methods of culturing, proliferating and expanding the same. The invention also provides methods of differentiating the placental stem cells. The invention further provides methods of using the placental stem cells in assays and for transplanting. | 12-25-2014 |
20150017140 | ORGANOIDS COMPRISING DECELLULARIZED AND REPOPULATED PLACENTAL VASCULAR SCAFFOLD - Provided herein are organoids comprising decellularized placental vascular scaffold comprising, or consisting of, a decellularized placental vascular scaffold, and methods of making and using the same. | 01-15-2015 |
20150017663 | IDENTIFICATION OF ANTITUMOR COMPOUNDS USING PLACENTA - Provided herein are methods of evaluating potential antitumor compounds, and thereby identifying antitumor compounds, using placenta or a portion thereof and tumor cells, and compositions for accomplishing the same. In one embodiment, provided herein is a method of determining whether a potential antitumor compound is effective against a plurality of tumor cells, comprising introducing a plurality of tumor cells to, e.g., into or onto, a mammalian placenta or portion thereof; contacting said plurality of tumor cells for a period of time with said antitumor compound; and determining whether said antitumor compound is effective against said tumor cells, wherein said antitumor compound is effective against said tumor cells if said antitumor compound over said period of time reduces the number of said tumor cells or reduces the growth rate of said tumor cells. | 01-15-2015 |
20150037316 | Placental Stem Cell Populations - The present invention provides placental stem cells and placental stem cell populations, and methods of culturing, proliferating and expanding the same. The invention also provides methods of differentiating the placental stem cells. The invention further provides methods of using the placental stem cells in assays and for transplanting. | 02-05-2015 |
Patent application number | Description | Published |
20120240167 | METHOD AND APPARATUS FOR PROVIDING WIRELESS SERVICE USING SCALABLE VIDEO CODING - A multimedia multicast-broadcast coverage capability is disclosed. The multimedia multicast-broadcast coverage capability is configured to provide wireless service coverage for multimedia multicast-broadcast services within an intended service coverage area including a plurality of wireless service regions. The wireless service coverage may be provided using properties of scalable video coding, where, for a given content item, different encoded layers of the content item are appropriately propagated to all or part of the intended coverage area. In one embodiment, a base encoded layer and one or more higher encoded layers, for providing basic and incrementally better quality versions of the content item, are appropriately propagated toward respective sets of the wireless service regions of the intended coverage area. In one embodiment, multiple encoded layers of lower quality are formed, from a content item of higher quality, and propagated toward each of the wireless service regions of the intended coverage area. | 09-20-2012 |
20130195068 | METHODS FOR TRANSMITTING AND RECEIVING CONTROL INFORMATION - In a method for receiving control information, a transceiver decodes at least one set of decoding candidates, and then detects whether control information is present on the control channel based on the decoded at least one set of decoding candidates. In a method for transmitting control information, a transceiver selects a decoding candidate from a set of decoding candidates for transmitting control information on a control channel; and transmits to another transceiver, control information using at least one time-frequency control channel resource element corresponding to the selected decoding candidate. | 08-01-2013 |
20130195100 | METHOD AND APPARATUS FOR SIGNALING TO SUPPORT FLEXIBLE REFERENCE SIGNAL CONFIGURATION - The method includes determining which of one or more physical resource elements are to include a reference signal. The method includes generating a signaling message including information indicating the determined physical resource elements that are to include a reference signal, and transmitting the signaling message to user equipment. | 08-01-2013 |
20130242750 | Method And Apparatus For Search Space Configuration For Enhanced Physical Downlink Control Channel - In one embodiment, the method of configuring a common search space (CSS) for at least one user equipment (UE) in a wireless communication system with at least a first type of physical downlink control channel includes broadcasting at least one parameter of a common search space (CSS), none of the parameters being the number of orthogonal frequency-division multiplex (OFDM) symbols. In one embodiment, a method of configuring a default user equipment-specific search space (USS) for a user equipment (UE) in a wireless communication system with at least a first type of physical downlink control channel includes broadcasting at least one parameter of the default USS, none of the parameters being based on an identifier of the UE. The broadcasting may occur before UE-specific signaling. In one embodiment, a method of configuring or reconfiguring the USS may include transmitting at least one parameter of the USS with UE-specific signaling. | 09-19-2013 |
20130308558 | METHOD AND APPARATUS FOR MULTI-MODE CONTROL INFORMATION ON UPLINK CHANNEL - One embodiment includes a method for selecting, by a mobile unit, one of a plurality of control information reporting modes based on at least one of a control information transmission type and a payload size. The method further includes transmitting, by the mobile unit, one or more UCI report(s) to the base station using the selected UCI reporting mode. | 11-21-2013 |
20140044062 | METHODS AND SYSTEMS FOR DETERMINING UPLINK RESOURCES - At least one example embodiment discloses a method of determining uplink resources. The method includes assigning index values for control channel elements, the control channel elements being allocated to at least one of first and second control channel transmission sets, the uplink resources being based on the index values, and an uplink resource for the first control channel transmission being different than an uplink resource for the second control channel transmission. | 02-13-2014 |
20140086135 | Method And Apparatus For Indicating EPDCCH Subframe Allocation - A method of specifying, for a user equipment (UE), non-enhanced physical downlink control channel (EPDCCH) subframes from among a plurality of subframes includes sending one or more first bitmaps from the base station to the UE, each of the one or more first bitmaps being logically mapped to the plurality of subframes and identifying first subframes, the first subframes being subframes, from among the plurality of subframes, that belong to one of one or more first groups; sending a second bitmap from the base station to the UE, the second bitmap being logically mapped to the first subframes and identifying the non-EPDCCH subframes from among the first subframes, the non-EPDCCH subframes being subframes that are not to be monitored by the UE for an EPDCCH; and sending the plurality of subframes from a base station to the UE. | 03-27-2014 |
20140092815 | METHOD AND APPARATUS FOR INDICATING PHYSICAL RESOURCE BLOCK PAIRS FOR EPDCCH - A method of specifying one or more sets of one or more physical resource block (PRB) pairs from among a plurality of PRB pairs in a subframe that a user equipment (UE) is to monitor for an enhanced physical downlink control channel (EPDCCH) includes sending, from a base station, a first representation of the PRB blocks, the representation including a plurality of bits, a total number of the plurality of bits being less than a product of total number of the plurality of PRB pairs and a total number of the one or more sets, the first representation indicating which of the plurality of PRB pairs are in at least one of the one or more sets of one or more PRB pairs the UE is to monitor for the EPDCCH. | 04-03-2014 |
20140092820 | METHODS AND APPARATUSES FOR ALLOCATING WIRELESS RESOURCES IN WIRELESS NETWORK - In a method for transmitting control information in a wireless network, a wireless resource allocation module assigns at least one of (i) a first plurality of enhanced resource element groups to a first set of enhanced control channel elements, and (ii) a second plurality of enhanced resource element groups to a second set of enhanced control channel elements; and a transceiver transmits the control information to at least one radio frequency equipment using at least one of the first and second sets of enhanced control channel elements. | 04-03-2014 |
20140219211 | METHOD AND APPARATUS FOR SEARCH SPACE CONFIGURATION FOR ENHANCED PHYSICAL DOWNLINK CONTROL CHANNEL - In one embodiment, the method of configuring a common search space (CSS) for at least one user equipment (UE) in a wireless communication system with at least a first type of physical downlink control channel includes broadcasting at least one parameter of a common search space (CSS), none of the parameters being the number of orthogonal frequency-division multiplex (OFDM) symbols. In one embodiment, a method of configuring a default user equipment-specific search space (USS) for a user equipment (UE) in a wireless communication system with at least a first type of physical downlink control channel includes broadcasting at least one parameter of the default USS, none of the parameters being based on an identifier of the UE. The broadcasting may occur before UE-specific signaling. In one embodiment, a method of configuring or reconfiguring the USS may include transmitting at least one parameter of the USS with UE-specific signaling. | 08-07-2014 |
20150092626 | METHODS AND SYSTEMS FOR TRANSMITTING AND RECEIVING UPLINK CONTROL CHANNEL INFORMATION - At least one example embodiment discloses a method of receiving uplink control information in a communication system having at least a first and a second cell in communication with a user equipment (UE), the first cell being using a time-division duplex (TDD) carrier and configured to communicate using TDD transmissions and the second cell using a frequency-division duplex carrier and configured to communicate using FDD transmissions, one of the first and second cells being a primary serving cell to the UE. The method includes receiving uplink control channel information on the frequency-division duplex carrier independent of which one of the first and second cells is the primary serving cell. | 04-02-2015 |
20150117233 | METHODS AND SYSTEMS FOR IMPLEMENTING A REPETITION LEVEL FOR A CHANNEL - At least one example embodiment discloses a user equipment (UE) including a memory configured to store a selected physical random access channel (PRACH) repetition level and a processor configured to monitor a duration of a timer, the duration indicating a length of time to use the PRACH repetition level. | 04-30-2015 |
Patent application number | Description | Published |
20090253744 | Acylated piperidine derivatives as melanocortin-4 receptor modulators - Certain novel N-acylated spiropiperidine derivatives are ligands of the human melanocortin receptor(s) and, in particular, are selective ligands of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of MC-4R, such as obesity, diabetes, nicotine addiction, alcoholism, sexual dysfunction, including erectile dysfunction and female sexual dysfunction. | 10-08-2009 |
20090325990 | ACYLATED SPIROPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS - Certain novel N-acylated spiropiperidine derivatives are ligands of the human melanocortin receptor(s) and, in particular, are selective ligands of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of MC-4R, such as obesity, diabetes, nicotine addiction, alcoholism, sexual dysfunction, including erectile dysfunction and female sexual dysfunction. | 12-31-2009 |
20110201615 | TRIAZOLE BETA CARBOLINE DERIVATIVES AS ANTI-DIABETIC AGENTS - Beta-carboline derivatives of structural formula (I) are selective antagonists of the somatostatin subtype receptor 3 (SSTR3) and are useful for the treatment of Type 2 diabetes mellitus and of conditions that are often associated with this disease, including hyperglycemia, insulin resistance, obesity, lipid disorders, and hypertension. The compounds are also useful for the treatment of depression and anxiety. | 08-18-2011 |
20140206673 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE - Provided are compounds of formula (I), wherein X, Y, Z, W, V, R | 07-24-2014 |
20140213580 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE - Provided are compounds with the following structure, formula (I) pharmaceutically acceptable salts thereof, use of those compounds for treating cancer and pharmaceutical compositions comprising those compounds. | 07-31-2014 |